When most researchers think of ADA2 deficiency (DADA2), they think of macrophages. And rightly so—monocytes and macrophages are the primary expressers of ADA2, and their dysregulation drives much of the vasculitis and inflammation seen in patients .
But limiting the story to myeloid cells misses half the picture.
DADA2 is not a pure autoinflammatory disease. It is a hybrid disorder with features of:
Autoinflammation (vasculitis, fevers, strokes)
Autoimmunity (lupus-like manifestations, cytopenias)
Immunodeficiency (hypogammaglobulinemia, infections)
This unique triad points to broad immune dysregulation extending well beyond the monocyte compartment. Recent research has revealed that ADA2 deficiency profoundly impacts T cells, B cells, and neutrophils, creating a distinct immune "signature" that can be detected through repertoire sequencing .
Understanding this full landscape is essential for developing therapies that address all aspects of DADA2—not just the vasculitis. And the AhelixBio ADA2 Knockout THP-1 Cell Line, while monocytic in origin, serves as a powerful tool for co-culture studies and mechanistic investigations into how myeloid dysfunction drives adaptive immune pathology.
A landmark 2025 study profiling 52 DADA2 patients revealed striking abnormalities in the adaptive immune system :
B-Cell Compromise:
65% of patients exhibited hypogammaglobulinemia (low immunoglobulins)
Memory B cells were significantly contracted
Expansion of CD21low B cells—a population associated with autoimmunity and chronic antigen stimulation
The B-cell receptor repertoire was skewed, particularly toward IgHV4-34 rearrangements (a signature linked to autoantibody production)
T-Cell Alterations:
Restricted T-cell receptor (TCR) repertoire diversity
Contraction of CD4 effector memory and central memory compartments
Despite normal CD4+ and CD8+ counts, functional impairments exist
The study went further: using machine learning, researchers could distinguish DADA2 patients from healthy individuals based solely on immunogenetic parameters—B-cell clone fraction, CDR3 length, and specific Kidera factors . This suggests that ADA2 deficiency leaves a molecular fingerprint on the entire adaptive immune system.
Why does this matter for your research? If you're studying DADA2, you cannot ignore B cells and T cells. The ADA2 KO THP-1 line allows you to investigate how ADA2-deficient myeloid cells instruct adaptive immune dysfunction—through co-culture experiments, cytokine profiling, and antigen presentation assays.
The B-cell abnormalities in DADA2 are not purely cell-intrinsic. Research has identified a critical defect in T follicular helper (Tfh) cells—the CD4+ T cells responsible for helping B cells produce high-affinity antibodies .
Key findings from DADA2 patient studies :
Frequency of circulating Tfh cells is increased, but they are functionally impaired
Tfh cells produce less IL-21—a cytokine essential for germinal center formation and B-cell differentiation
This defective Tfh-B cell interaction likely contributes to the hypogammaglobulinemia seen in the majority of patients
The B-cell intrinsic defect: Even when stimulated in vitro, B lymphocytes from DADA2 patients secrete nonfunctional ADA2 protein and exhibit impaired proliferation and differentiation . This suggests that ADA2 plays a role within B cells themselves—not just in the myeloid cells that support them.
How the ADA2 KO THP-1 line fits in: While THP-1 cells are not B cells or T cells, they are the perfect "training ground" for studying monocyte-T-cell crosstalk. Co-culture experiments with primary T cells and ADA2 KO THP-1-derived macrophages can reveal how myeloid ADA2 deficiency alters T-cell polarization, Tfh differentiation, and cytokine support for B cells.
The vasculitis in DADA2—affecting medium and small vessels—has long been a clinical puzzle. Emerging evidence points to neutrophils as central players .
What is NETosis?
Neutrophil extracellular traps (NETs) are web-like structures of DNA and antimicrobial proteins that neutrophils release to trap pathogens. But when NETosis is dysregulated, it damages blood vessels and fuels inflammation.
The DADA2-NETosis connection :
Patients with active DADA2 have an abundance of circulating low-density granulocytes (LDGs)—a neutrophil subset prone to spontaneous NET formation
Adenosine itself triggers NETosis in DADA2 neutrophils, acting through A1 and A3 adenosine receptors
NETs from DADA2 patients, when incubated with M1 macrophages, drive significantly higher TNF-α production
Anti-TNF therapy reduces LDG abundance and spontaneous NET formation
The therapeutic implication: The study identified that recombinant ADA2 inhibits adenosine-induced NETosis, as do A1/A3 receptor antagonists and A2A receptor agonists . This opens the door to targeted therapies that modulate NET formation—beyond broad immunosuppression.
How this connects to the ADA2 KO THP-1 line: While THP-1 cells are not neutrophils, they are ideal for studying NET-mediated macrophage activation. Using our KO line, you can:
Generate ADA2-deficient macrophages
Isolate NETs from DADA2 patient neutrophils (or generate NETs in vitro)
Quantify macrophage cytokine responses to NET exposure
Screen for compounds that block NET-induced macrophage activation
This co-culture approach bridges the myeloid-neutrophil axis critical to DADA2 pathogenesis.
Anti-TNF therapies (etanercept, adalimumab, infliximab) are first-line treatments for DADA2 vasculitis and have dramatically improved outcomes—particularly in preventing new strokes .
But here's the catch: not all inflammation resolves .
A detailed cytokine analysis of DADA2 patients on anti-TNF therapy revealed persistently elevated levels of:
TNF (despite treatment—suggesting incomplete blockade or alternative sources)
IL-8 (a neutrophil chemoattractant)
Multiple interferons (IFN signature)
BAFF and APRIL (B-cell survival factors)
sCD40L (T-cell activation marker)
This persistent cytokine elevation helps explain why some manifestations—particularly hematologic abnormalities (anemia, thrombocytopenia, neutropenia) and hypogammaglobulinemia—do not fully respond to anti-TNF therapy . Alternative pathways are at play.
The research opportunity: The ADA2 KO THP-1 line allows you to dissect which cytokines are myeloid-derived versus derived from other cell types. By measuring the secretory profile of KO macrophages under various conditions, you can identify targets for combination therapies that address the full spectrum of DADA2 inflammation.
The AhelixBio ADA2 Knockout THP-1 Cell Line is the foundation for studying how myeloid ADA2 deficiency shapes the broader immune system.
| Research Question | Experimental Approach with AhelixBio's KO Line |
|---|---|
| How does ADA2-deficient monocyte-derived macrophages affect T-cell polarization? | Co-culture KO macrophages with naïve CD4+ T cells; measure Th1/Th2/Tfh differentiation by flow cytometry and cytokine ELISA |
| Does myeloid ADA2 deficiency alter B-cell support? | Co-culture KO macrophages with primary B cells; measure B-cell survival, proliferation, and antibody secretion |
| How do NETs activate ADA2-deficient macrophages? | Isolate NETs from healthy or DADA2 neutrophils; add to WT vs. KO macrophages; quantify TNF-α, IL-6, IL-1β |
| Can we rescue the adaptive immune defects with ADA2 enzyme? | Treat KO macrophages with recombinant ADA2; measure changes in cytokine profile and T-cell polarizing capacity |
DADA2 is not a "macrophage disease." It is a multi-lineage immune disorder whose full picture requires integrating:
Myeloid biology (monocytes, macrophages, dendritic cells)
Lymphoid biology (T cells, B cells, Tfh cells)
Granulocyte biology (neutrophils, NETosis)
The ADA2 KO THP-1 line gives you a stable, scalable, human-relevant platform to interrogate the myeloid hub of this network—and then extend your findings to adaptive immune partners through co-culture.
The AhelixBio ADA2 Knockout THP-1 Cell Line is more than a tool for studying macrophages. It is your gateway to understanding how ADA2 deficiency dysregulates T cells, B cells, neutrophils, and the adaptive immune repertoire.
Whether you are:
Investigating the B-cell defects underlying hypogammaglobulinemia...
Probing the Tfh cell dysfunction that impairs antibody responses...
Or screening for therapies that block NETosis-driven inflammation...
...this cell line provides the reproducible, validated myeloid platform you need.
Order the AhelixBio ADA2 KO THP-1 Cell Line today and see the full immune picture.
